Middellangetermijnoverleving na open versus robotgeassisteerde radicale cystectomie in Nederland:resultaten van de ‘SNAPSHOT’ cystectomie ; Intermediate term survival following open versus robot-assisted radical cystectomy in the Netherlands:results of the Cystectomie SNAPSHOT study

There is insufficient knowledge on intermediate-term survival of non-metastatic muscle-invasive bladder cancer (MIBC) after open (ORC) versus robot-assisted (RARC) cystectomy, with or without neo-adjuvant chemotherapy (NAC). This retrospective study was performed in 19 Dutch hospitals between 2012 and 2015 to assess the five-year survival after both interventions and the influence of NAC. Out of 1,534 cT1-4N0-1-patients, 1,086 patients were treated with ORC and 389 with RARC. The 5‑year survival rate after ORC was 51% (95% CI 47–53) versus 58% after RARC (95% CI 52–63), hazard ratio 1.00 (95%... Mehr ...

Verfasser: van Ginkel, Noor
Vis, André N.
Boormans, Joost L.
van der Poel, Henk G.
van der Schoot, Deric K. E.
Aben, Katja K. H.
Hermans, Tom J. N.
Meijer, Dennie
Voortman, Jens
Arends, Tom J. H.
Ausems, Peter J.
Baselmans, Dorine
Berger, Christian P. A. M.
Berrens, Anne-Claire
Bickerstaffe, Henry
Bos, Siebe D.
Braam, Marlene
Buddingh, K. Tim
Claus, Sebastiaan
Dekker, Karen
van Doeveren, Thomas
Einerhand, Sarah M. H.
Fossion, Laurent M. C. Laurent
Hinsenveld, Florentien J.
van Gennep, Erik J.
Grondhuis Palacios, Lorena A.
Hobijn, Mandy M.
van Huystee, Suzanne H.
Jaspers-Valentijn, Martinique
Klaver, O. Sjoerd
Koldewijn, Evert L.
Korsten, Linn
Lenting, Anne
Lentjes, Koen J.
Luiting, Henk B.
van der Meer, Saskia
Mertens, Laura
Nieuwenhuijzen, Jakko A.
Noordzij, M. Arjen
Nooter, Ronald I.
Notenboom, Marije
Oomen, Robert J. A.
van Roermund, Joep G. H.
de Rooij, Judith
Roshani, Hossain
Schrier, Bart P.
van der Slot, Michelle A.
Somford, D. M. Rik
Stelwagen, Piter-Jan
Stroux, Aukje M. A.
van der West, Alwine
Wijsman, Bart P.
Windt, Willemijn A. K. M.
van Zanten, Paul
van Beek, Sytse C.
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: van Ginkel , N , Vis , A N , Boormans , J L , van der Poel , H G , van der Schoot , D K E , Aben , K K H , Hermans , T J N , Meijer , D , Voortman , J , Arends , T J H , Ausems , P J , Baselmans , D , Berger , C P A M , Berrens , A-C , Bickerstaffe , H , Bos , S D , Braam , M , Buddingh , K T , Claus , S , Dekker , K , van Doeveren , T , Einerhand , S M H , Fossion , L M C L , Hinsenveld , F J , van Gennep , E J , Grondhuis Palacios , L A , Hobijn , M M , van Huystee , S H , Jaspers-Valentijn , M , Klaver , O S , Koldewijn , E L , Korsten , L , Lenting , A , Lentjes , K J , Luiting , H B , van der Meer , S , Mertens , L , Nieuwenhuijzen , J A , Noordzij , M A , Nooter , R I , Notenboom , M , Oomen , R J A , van Roermund , J G H , de Rooij , J , Roshani , H , Schrier , B P , van der Slot , M A , Somford , D M R , Stelwagen , P-J , Stroux , A M A , van der West , A , Wijsman , B P , Windt , W A K M , van Zanten , P & van Beek , S C 2023 , ' Middellangetermijnoverleving na open versus robotgeassisteerde radicale cystectomie in Nederland : resultaten van de ‘SNAPSHOT’ cystectomie ' , Tijdschrift voor Urologie , vol. 13 , no. 8 , pp. 164-175 . https://doi.org/10.1007/s13629-023-00409-x
Sprache: Niederländisch
Permalink: https://search.fid-benelux.de/Record/base-26845655
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://research.vumc.nl/en/publications/229f7fc6-51f4-45df-a79d-667606c93839

There is insufficient knowledge on intermediate-term survival of non-metastatic muscle-invasive bladder cancer (MIBC) after open (ORC) versus robot-assisted (RARC) cystectomy, with or without neo-adjuvant chemotherapy (NAC). This retrospective study was performed in 19 Dutch hospitals between 2012 and 2015 to assess the five-year survival after both interventions and the influence of NAC. Out of 1,534 cT1-4N0-1-patients, 1,086 patients were treated with ORC and 389 with RARC. The 5‑year survival rate after ORC was 51% (95% CI 47–53) versus 58% after RARC (95% CI 52–63), hazard ratio 1.00 (95% CI 0.84–1.20) after multivariable analysis. 226 of 965 cT2-4aN0 patients were treated with NAC. More patients had ypT0 after NAC than after no NAC (31% vs 15%; p < 0.01). The best five-year survival was in patients with ypT0 after NAC (89%; 95% CI 81–97). This study shows similar five-year survival of MIBC patients treated with ORC or RARC and shows that the best survival was after NAC.